Jeri Hilleman

Current public company boards: Hillevax, Minerva Neurosciences, Novocure, SI-Bone

Prior public company boards: Talis Biomedical Corp., Xenoport

Executive Experience: Jeri Hilleman has served as the chief financial officer of Intersect ENT since 214, just prior to their IPO. She brings over 2 years of experience as a CFO, including taking 5 companies public. Previously, she served as CFO of public companies including Amyris (NASDAQ: AMRS), a renewable products company, Symyx Technologies (acquired), a materials science research, instrumentation and software company, Ocera (acquired), a biopharma company, and Cytel (acquired), an immunotherapy company.

Jeri is a member of the board of directors and audit committees of Novocure (NASDAQ: NVCR), a commercial global oncology company, and Minerva Neurosciences (NASDAQ: NERV), a biopharma company focused on central nervous system disorders, and she served previously as a member of the board of directors and chair of the audit committee of Xenoport, Inc. (acquired), a commercial biopharma company.

Additional information: Jeri holds an AB from Brown University and an MBA from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.